1. Home
  2. HWBK vs STTK Comparison

HWBK vs STTK Comparison

Compare HWBK & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HWBK

Hawthorn Bancshares Inc.

N/A

Current Price

$35.31

Market Cap

240.2M

Sector

Finance

ML Signal

N/A

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$4.03

Market Cap

275.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HWBK
STTK
Founded
1865
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
240.2M
275.9M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
HWBK
STTK
Price
$35.31
$4.03
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.20
AVG Volume (30 Days)
4.2K
375.1K
Earning Date
04-29-2026
01-01-0001
Dividend Yield
2.38%
N/A
EPS Growth
1764.29
27.32
EPS
2.53
N/A
Revenue
N/A
$5,721,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.96
N/A
Revenue Growth
N/A
245.26
52 Week Low
$25.21
$0.69
52 Week High
$36.25
$4.89

Technical Indicators

Market Signals
Indicator
HWBK
STTK
Relative Strength Index (RSI) 57.01 51.33
Support Level $34.02 $3.52
Resistance Level $36.06 $4.23
Average True Range (ATR) 0.67 0.28
MACD -0.04 0.00
Stochastic Oscillator 65.82 58.62

Price Performance

Historical Comparison
HWBK
STTK

About HWBK Hawthorn Bancshares Inc.

Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: